Cargando…

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent

The nocebo effect is defined as the incitement or the worsening of symptoms induced by any negative attitude from non-pharmacological therapeutic intervention, sham, or active therapies. When a patient anticipates a negative effect associated with an intervention, medication or change in medication,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kristensen, Lars Erik, Alten, Rieke, Puig, Luis, Philipp, Sandra, Kvien, Tore K., Mangues, Maria Antonia, van den Hoogen, Frank, Pavelka, Karel, Vulto, Arnold G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Current Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182448/ https://www.ncbi.nlm.nih.gov/pubmed/30269270 http://dx.doi.org/10.1007/s40259-018-0306-1

Ejemplares similares

Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure
por: Cornes, Paul, et al.
Publicado: (2020)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar
por: Petit, Juliette, et al.
Publicado: (2021)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

Pharmacovigilance Considerations for Biosimilars in the USA
por: Grampp, Gustavo, et al.
Publicado: (2015)

An Efficient Development Paradigm for Biosimilars
por: Webster, Christopher J., et al.
Publicado: (2019)

Pharmacokinetics and Generic Drug Switching: A Regulator’s View
por: Glerum, Pieter J., et al.
Publicado: (2020)

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
por: Cohen, Hillel P., et al.
Publicado: (2022)

The Importance of Countering Biosimilar Disparagement and Misinformation
por: Cohen, Hillel P., et al.
Publicado: (2020)

A ‘Global Reference’ Comparator for Biosimilar Development
por: Webster, Christopher J., et al.
Publicado: (2017)

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
por: Fleischmann, Roy, et al.
Publicado: (2020)

Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect
por: Rezk, Mourad F., et al.
Publicado: (2017)

The Clinical Implications of Nocebo Effects for Biosimilar Therapy
por: Colloca, Luana, et al.
Publicado: (2019)

The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders
por: Grampp, Gustavo, et al.
Publicado: (2015)

Biosimilars: How Can Payers Get Long-Term Savings?
por: Mestre-Ferrandiz, Jorge, et al.
Publicado: (2016)

Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices
por: Ebbers, Hans C., et al.
Publicado: (2016)

The nocebo effect challenges the non-medical infliximab switch in practice
por: Boone, N. W., et al.
Publicado: (2018)

Biosimilars: To switch or not to switch – that is the question
por: Szekanecz, Zoltán
Publicado: (2020)

Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
por: Cohen, Hillel P., et al.
Publicado: (2023)

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)

To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
por: Rezk, Mourad F., et al.
Publicado: (2018)

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
por: Goldsmith, David, et al.
Publicado: (2018)

Probiotic lactic acid bacteria – the fledgling cuckoos of the gut?
por: Berstad, Arnold, et al.
Publicado: (2016)

Correction to: To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
por: Rezk, Mourad F., et al.
Publicado: (2018)

The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice
por: Kravvariti, Evrydiki, et al.
Publicado: (2019)

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
por: Spanou, Ioanna, et al.
Publicado: (2019)

Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
por: Pavelka, Karel, et al.
Publicado: (2016)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Pharmacological Management of Borderline Personality Disorder and Common Comorbidities
por: Pascual, Juan C., et al.
Publicado: (2023)

The Effect of Television and Print News Stories on the Nocebo Responding Following a Generic Medication Switch
por: MacKrill, Kate, et al.
Publicado: (2020)

Challenges in the Pharmacologic Management of Obesity and Secondary Dyslipidemia in Children and Adolescents
por: Kennedy, Mary Jayne, et al.
Publicado: (2013)

Biosimilar switching – current state of knowledge
por: Wiland, Piotr, et al.
Publicado: (2018)

Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines
por: Sultana, Janet, et al.
Publicado: (2020)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
por: Peters, Bas J. M., et al.
Publicado: (2021)

Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV
por: Eke, Ahizechukwu C., et al.
Publicado: (2020)

Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic
por: Torres, Tiago, et al.
Publicado: (2020)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019)

Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma
por: Kunos, Charles A., et al.
Publicado: (2020)

The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies
por: Odinet, Johlee S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tbar64j4a136uh5q8mhlcj9am1